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Abstract
Parkinson’s disease is a neurodegenerative disorder characterized by Lewy bodies, a pathological hallmark comprised
mostly of aggregated alpha synuclein. Accumulating evidence demonstrates the association of smaller oligomeric
aggregates to disease etiology and many therapeutic approaches are aimed at inhibiting and reducing the aggregation
process. Molecular chaperones and co-chaperones play a key role in protein homeostasis and have potential as therapeutics
to inhibit alpha synuclein associated toxicity. Here we use a gene therapy approach to evaluate the applicability of the
Hsp70 co-chaperone CHIP (C-terminal Hsp70 interacting protein) as a therapeutic candidate and examine its direct effect on
alpha synuclein aggregates in vivo. Utilizing a novel viral vector mediated rat model to directly detect alpha synuclein
aggregates, we show that CHIP can mediate the degradation of alpha synuclein aggregates in vivo. However, our studies
also reveal that CHIP may potentially degrade tyrosine hydroxylase which would compromise the applicability of CHIP as a
therapeutic approach for Parkinson’s disease.
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Introduction
Many neurodegenerative diseases share the common charac-
teristic of protein misfolding and consequent aggregation leading
to cell death. In the case of alpha-synucleinopathies including
Parkinson’s disease (PD), many lines of evidence demonstrate a
strong association between alpha synuclein (a-syn) aggregation
and neurodegeneration [1,2,3,4]. Although the identity of toxic a-
syn aggregates remains to be determined, many disease modifying
therapeutic approaches aim to inhibit and reduce the aggregation
process [5]. The physiological role of molecular chaperones and
co-chaperones in protein homeostasis offers a promising thera-
peutic approach for synucleinopathies, with multiple studies
demonstrating that a reduction in a-syn protein levels reduces
oligomerization and rescues neurotoxicity [6,7]. Having previously
demonstrated the ability of the co-chaperone C-terminus Hsp70
interacting protein (CHIP) to target toxic a-syn aggregates for
degradation in vitro [8,9], we now describe the modulation of a-syn
aggregates by CHIP in vivo in a novel viral-vector mediated rat
model [10]. In this model the direct detection of a-syn aggregates
using in vivo protein-fragment complementation facilitates the
examination and quantitation of CHIP-induced modulation of a-
syn aggregates in vivo. We demonstrate that co-expression of CHIP
results in a significant reduction in a-syn aggregates in vivo.
Somewhat surprisingly, our results also indicate that tyrosine
hydroxylase may be a substrate for CHIP-mediated degradation
which would preclude CHIP as a potential treatment for PD and
synucleinopathies. Nonetheless, we demonstrate the direct visual-
ization of a-syn degradation in vivo and validate the applicability of
our animal model in examining potential therapeutic approaches
that target a-syn aggregates.
Results
We have recently described a novel rat viral vector model with
the capability to directly detect and visualize a-syn aggregates ex
vivo and in vivo by monitoring venusYFP fluorescence [10]. This is
achieved using an in vivo complementation assay with targeted co-
delivery of AAV-venus1-synuclein and AAV-synuclein-venus2
(AAV-V1S+ AAV-SV2) into the SNpc, which results in a-syn-
induced neurodegeneration in the SNpc and reconstitution of
venusYFP fluorescence along the nigrostriatal pathway. In the
current study we examine if the Hsp70 co-chaperone protein
CHIP can reduce a-syn oligomerization and concomitantly rescue
a-syn–induced neurotoxicity in vivo.
The SNpc of Sprague Dawley rats was unilaterally co-injected
with AAV8-V1S, AAV8-SV2 and AAV8-myc-CHIP (syn+CHIP)
or AAV8-V1S, AAV8-SV2 and empty AAV (syn-CHIP) or
AAV8-myc-CHIP, AAV8-venusYFP and empty AAV (ve-
nus+CHIP) and sacrificed 8 weeks post injection. Post mortem
microscopic analyses reveals the direct detection of a-syn-
venusYFP in the SNpc, as described previously [10] and
immunohistochemical analyses shows co-expression of CHIP with
venusYFP fluorescence in the cells of the SNpc. These data
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indicate efficient co-transduction and co-expression of all three
injected AAVs (Fig. 1A). As expected, no expression is detected
contralateral to the injection site as described previously [10]. The
cellular levels of a-syn and venusYFP fluorescence in cell soma and
processes were examined in coronal sections of the SNpc using the
human specific anti-a-syn antibody 4B12 (Fig. 1B). Interestingly,
in rats co-expressing CHIP and a-syn venusYFP fluorescence was
reduced by 50% compared to control animals (Fig. 1C). In the
same regions of interest (ROIs), a-syn immunostaining was
reduced by 15% in CHIP expressing animals compared to control
animals (Fig. 1C). Detailed image analysis of the SNpc revealed a
35% reduction in the number of venusYFP positive cells (Fig. 1D)
as well as a 4-fold decrease in the average fluorescence per cell in
CHIP-transduced rats compared to control rats (Fig. 1E).
To determine if CHIP-mediated degradation of a-syn aggre-
gates is responsible for the observed reduction in venusYFP
fluorescence we performed immunoblot analyses of striatal
homogenates from the same animals. We have previously shown
that a-syn aggregates can be detected in the striatum following
injection of AAV-V1S and AAV-SV2 into SNpc. Here, striatal
homogenates were analyzed using both SDS-PAGE and native
PAGE to determine the level of a-syn aggregates present (Fig. 2).
In order to exclude endogenous a-syn from our analyses, western
blots were incubated with human specific anti a-syn antibody
4B12. High molecular weight species were detected by native
PAGE confirming the formation of aggregates in this model
(Fig. 2A). Furthermore, densitometry revealed a reduction in high
molecular weight a-syn species in syn+CHIP animals (n = 6)
compared to syn-CHIP animals (n = 3) indicating a reduction in a-
syn aggregates (Fig. 2B). The total amount of human a-syn was
quantified using SDS-PAGE (Fig. 2C). V1S (31 kDa) and SV2
(22 kDa) were reduced by 26% (Fig. 2D) and 69% (Fig. 2E)
respectively in CHIP animals. .
We have previously demonstrated a-syn-mediated neurotoxicity
in rats injected with V1S+SV2 in the SNpc [10]. To determine if
co-expression of CHIP is neuroprotective in vivo we examined
neuronal survival in the SNpc of CHIP transduced rats compared
to control rats 8 weeks post injection. Coronal sections of SNpc
were immunostained for tyrosine hydroxylase (TH) and TH
immunopositive neurons in ipsilateral and contralateral SNpc
were quantified using unbiased stereology (Fig. 3A). As expected, a
34% lesion was calculated in the syn-CHIP group (n = 10).
Surprisingly, a significant 35% (n= 7) lesion was observed in the
syn+CHIP group despite a significant decrease in a-syn aggrega-
tion (Fig. 3B). Unexpectedly, a 44% lesion was also detected in the
venus+CHIP group (n= 4) expressing full length venus and CHIP
(Fig. 3B). To confirm the extent of the lesion within the SNpc we
conducted secondary analyses using the neuronal marker NeuN.
Coronal sections of the SNpc were co-immunostained with anti-
TH antibody (Fig. 4A) and anti-NeuN antibody (Fig. 4B). Co-
staining with TH and NeuN allowed us to delineate the SNpc
based on TH immunostaining ipsilateral and contralateral (Fig.
S1), and to then assess the number of neurons within that region
using the NeuN immunostaining (Fig. 4C). We then compared cell
counts of TH immunopositive cells to NeuN immunopositive cell
counts for each animal (Fig. 4D & E). Recounting of NeuN
immunopositive cells within the delineated SNpc revealed no
neurodegeneration in animals co-expressing CHIP. Instead, our
analyses revealed the difference between the lesion determined by
NeuN compared to that determined by TH immunostaining
(Fig. 4F). Significant neuronal loss was confirmed to persist in the
syn-CHIP group (Fig. 4G).
Discussion
Toxicity of a-syn aggregates is the focus of many disease
modifying therapeutic approaches for PD. We have recently
described a novel rat model enabling the direct visualization of a-
syn aggregates along the nigrostriatal pathway [10]. This novel
model offers a powerful tool with which to examine potential
therapeutic approaches targeting a-syn aggregates and is the focus
of the work presented herein. Molecular chaperones have been
previously shown to degrade a-syn aggregates and thus are natural
candidates in the search for disease modifying agents [6,7].
Specifically, the co-chaperone CHIP has been shown by our
laboratory to degrade and reduce a-syn aggregates in vitro [8,9].
Here we used a gene therapy approach to overexpress the co-
chaperone CHIP in the SNpc of model rats to determine the
ability of CHIP to modify a-syn aggregates in vivo and rescue a-syn
induced neurodegeneration. Post-mortem immunohistological
analyses of rats co-injected with AAV-V1S + AAV-SV2 + AAV-
CHIP (syn+CHIP) revealed substantial co-staining of venusYFP
and CHIP. Since venusYFP fluorescence occurs only upon co-
transduction of V1S and SV2, the observed co-expression with
CHIP demonstrates the efficient co-transduction of all three
viruses in neurons of the SNpc.
The significant reduction in venusYFP fluorescence within cells,
as well as the reduction in the number of venusYFP positive cells
following CHIP expression, is indicative of a CHIP-associated
reduction of a-syn aggregates. These results also demonstrate our
ability to directly detect changes in a-syn aggregate formation,
thus emphasizing the advantage of our novel animal model as a
tool to test potential therapeutic approaches targeting a-syn
aggregates.
Further biochemical analyses showed a significant reduction in
the total protein levels of a-syn as well as a reduction in a-syn
aggregates which supports CHIP-mediated degradation of a-syn,
in accordance with our previous studies demonstrating degrada-
tion in vitro [8]. However, the exact mechanism by which CHIP
degrades a-syn aggregates in vivo remains to be determined as it
was demonstrated by us and others that CHIP can target proteins
for degradation via both the lysosomal and proteasomal pathways
[11,12], in both a HSP dependent and independent manner [13].
There is a possibility that the observed reduction in a-syn
immunostaining is attributable to the simultaneous co-expression
of three proteins. Arguing against this possibility is the differential
decrease in SV2 versus V1S expression (Fig. 2D and 2E), which
suggests an active degradation process, rather than a passive
reduction, which would be expected to affect all proteins to the
same extent. Further, the differential degradation of SV2 over V1S
should be taken into consideration when comparing the level of
venusYFP fluorescence to immunostaining of a-syn. Simply put,
degradation of SV2 will result in reduced venusYFP fluorescence
but the remaining V1S would still be detected with immunostain-
ing. This is the most likely explanation for the significant reduction
in venusYFP fluorescence observed in the SNpc compared to the
non-significant reduction in a-syn staining.
In this study we have used two different cellular markers, TH
and NeuN, to determine neuronal survival. In both the syn-CHIP
group and the syn+CHIP group we detected a loss of TH
immunopositive cells in the SNpc. Unexpectedly, we also detected
a loss of TH immunopositive cells in the SNpc of the venus+CHIP
group. Since this group does not overexpress a-syn, the apparent
neuronal loss could not be associated with a-syn. Even though we
have previously shown that overexpression of CHIP and
venusYFP is non-toxic [8,9,10], this result could be interpreted
as CHIP-mediated neurotoxicity. However the fact that CHIP has
CHIP-Mediated Degradation of Alpha-Synuclein
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been demonstrated to be non-toxic in vitro, led us to question TH
as a valid dopaminergic cell marker by which to determine
neurodegeneration in the SNpc. The fact that CHIP is an E3-
ubiquitin ligase with several know substrates [14,15] raises the
possibility of CHIP-mediated degradation of TH, which may
appear as neuronal loss. In other words, viable dopaminergic
neurons expressing CHIP would be wrongly excluded from our
analysis when counting TH immunopositive cells because of
CHIP-mediated TH degradation. To address this potential
conflict we conducted a second stereological analysis using NeuN
as a marker to determine neuronal viability in the SNpc. This
approach allowed us to not only re-evaluate possible CHIP-
associated cell loss but also allowed us to indirectly examine the
possibility of CHIP-mediated degradation of TH. Re-analysis of
NeuN immunopositive cells in the SNpc demonstrated a
significantly greater number of neurons ipsilateral to the injection
Figure 1. Reduced venusYFP fluorescence in the presence of CHIP. Coronal sections of the SNpc were immunostained with anti-Myc (alexa-
635, purple) to evaluate co-expression of CHIP with a-syn aggregates (venusYFP, green). Images revealed extensive co-expression of CHIP and a-syn
aggregates demonstrating efficient viral co-transduction (A). Coronal Sections were imaged for venusYFP fluorescence and a-syn immunostaining
(red) to evaluate the level of a-syn aggregates (B). Image analysis demonstrates in syn+CHIP group (+CHIP) a significant reduction in the overall
venusYFP fluorescence and no change in a-syn immunostaining compared to syn-CHIP (2CHIP)(C). Detailed image analysis shows a significant 35%
reduction in the number of venusYFP positive cells in the syn+CHIP group compared to syn-CHIP (D) as well as a 4-fold reduction in venusYFP
fluorescence per cell compared to control (E). Representative images are displayed. Scale bars 200 mm.
doi:10.1371/journal.pone.0092098.g001
Figure 2. CHIP reduces the amount of human a-syn in the striatum. Striatal homogenates were biochemically analyzed for a-syn levels.
Higher molecular weight a-syn species are visible in native-PAGE (A). Band quantification revealed a 43% reduction in a-syn aggregates measured in
the syn+CHIP group (+CHIP) compared to the syn-CHIP group (2CHIP) (B). Denatured samples were also run on SDS-PAGE to evaluate the total
amount of a-syn. The higher band at ,31.3 KD and lower band at ,22.4 KD detected with anti-a-syn correspond to V1S and SV2 respectively (C). A
26% and a 69% reduction were measured in both V1S and SV2 respectively in animals expressing CHIP (D and E).
doi:10.1371/journal.pone.0092098.g002
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site. Furthermore, NeuN immunostaining revealed the absence of
cell loss in both groups expressing CHIP, whereas significant
neuronal loss was still apparent in the syn-CHIP group. The
conflicting neuronal counts determined by TH versus NeuN in the
+CHIP groups, support our original hypothesis that CHIP may
target TH for degradation and may be neuroprotective. However,
the lack of significant cell loss via NeuN staining in the +CHIP
groups, should be interpreted with caution given the fact that cell
loss was apparent when TH immunopositive cells were quantified
Taken together, the immunohistochemical analysis conducted in
Figure 3. TH cell loss in the presence of CHIP. Unbiased blinded stereological analysis of TH immunopositive cells in coronal sections across the
SNpc was performed using DAB (A). Cell loss is determined by the ratio of TH positive cells ipsilateral (right, asterisk) to contralateral (left). A 34%
lesion and a 35% lesion were measured in the syn–CHIP group (n = 10, p,0.005) and syn+CHIP group (n = 7, p,0.005) respectively (B). The
venus+CHIP group expressing only venusYFP and CHIP had a 44% lesion (n = 4, p,0.05). Representative images are displayed. Scale bar 500 mm.
doi:10.1371/journal.pone.0092098.g003
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Figure 4. NeuN quantification in the presence of CHIP. Blinded stereological analysis of NeuN immunopositive cells in coronal sections across
the SNpc was performed. Sections were co-stained with anti TH antibody (A., purple) and NeuN (B., red). A binary image was produced where the
SNpc is delineated according to the TH immunostaining (C., blue). Comparison of percent cell loss per animal revealed discrepancies in the TH
measured lesion compared to NeuN in the presence of CHIP (E), unlike animals not expressing CHIP (D). We found a 20–30% difference in lesions
determined by NeuN to that determined by TH in the presence of CHIP (F). A significant 23% NeuN lesion was measured in the syn–CHIP group
whereas no significant lesion was measured in the venus+CHIP group and syn+CHIP (F). Scale bars 200 mm. For the purpose of illustrating the image
analysis conducted in this assay only representative images of CHIP animal are presented.
doi:10.1371/journal.pone.0092098.g004
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this study is insufficient to definitively determine the exact effect of
CHIP on neuronal survival despite the CHIP-mediated degrada-
tion of a-syn aggregates that was observed. Irrespective, the
possibility that CHIP targets tyrosine hydroxylase for degradation
precludes it as a possible therapeutic intervention for PD since TH
is a rate-limiting enzyme in the conversion of the amino acid
tyrosine to the neurotransmitter dopamine [16], which is depleted
in PD.. Although CHIP may not ultimately be a suitable
therapeutic approach for PD, it is still a valid approach for other
protein-misfolding diseases such as Alzheimer’s disease and
Huntington’s disease and was previously shown to degrade protein
aggregates implicated in both diseases [12,17,18].
Here we examine the direct delivery of a viral vector expressing
the co-chaperone CHIP into the SNpc of a unique PD rat model
as a gene therapy approach to reduce a-syn-induced neurotoxicity.
Despite the described limitations, this work demonstrates the
potential of our novel model for evaluating therapeutic candidates,




The viral vectors pAAV-CBA-VENUS1-SYNUCLEIN-WPRE
(V1S) and pAAV-CBA-SYNUCLEIN-VENUS2-WPRE (SV2)
were constructed by inserting the human a-syn cDNA, fused to
either the N-terminus half of venusYFP (V1S) or the C-terminus
half of venusYFP (SV2), into the EcoRV and NheI sites of the
pAAV-CBA-WPRE vector [7]. pAAV-CBA-VenusYFP-WPRE
was constructed by inserting the venusYFP cDNA into the XhoI
and NheI sites of pAAV-CBA-WPRE vector. pAAV-CBA-myc-
CHIP was constructed by inserting the myc-tagged CHIP cDNA
into pAAV-CBA-WPRE vector. AAV serotype 8 was produced by
the Harvard Gene Therapy Initiative as previously described [19].
Injections
Sprague Dawley rats (300–350 gram) were anesthetized with
intraperitoneal injection of ketamine/xylazine and placed in a
stereotaxic frame. The surgical site was shaved and sterilized with
betadine prior to making a 2 cm incision along the midline. The
scalp was exposed and a unilateral injection targeting the SN was
performed at coordinates AP 25.2, ML 22 and DV 27.4 with
bregma as a point of reference. For each animal, a total volume of
3 ml of virus was injected at a rate of 0.2 ml/min using a
microinjection pump and 10 ml Hamilton syringe with a 30-gauge
needle. For V1S+ SV2+ CHIP group 1 ml of AAV8- V1S (8.3N1012
viral genome/ml), 1 ml of AAV8-SV2 (8.7N1012 viral genome/ml)
and 1 ml of AAV8- CHIP (1.2N1013 viral genome/ml) were
coinjected; for the V1S+ SV2- CHIP group (control), 1 ml of
AAV8- V1S and 1 ml of AAV8-SV2 were coinjected. This group
included several animals injected with additional 1 ml of an empty
AAV8. Animals in the venusYFP+CHIP group (venus+CHIP)
were injected with 1 ml of AAV8-venusYFP (1N1012 viral genome/
ml), 1 ml of AAV8-myc-CHIP and 1 ml an empty AAV8. At the
end of injection period the needle remained in place for 5 minutes
before gradual removal.
All studies were performed with the approval of the Massachu-
setts General Hospital Animal Care and Use Committee and in
compliance with the National Institute of Health guidelines for the
use of experimental animals.
Tissue processing
At 8 weeks post-injection, rats were deeply anesthetized and
transcardially perfused with 0.01 M phosphate buffered saline
(PBS, pH7.4, Sigma) followed by brain extraction. The striatum
was freshly dissected for biochemical analysis prior to post fixation
of the midbrain, which allowed us to conduct biochemical and
histological analysis from the same animal. Brains were post-fixed
for 24–72 hours and transferred to a solution of 30% sucrose in
PBS. Frozen brains were sectioned at 40 mm on a sliding
microtome and kept in a cryoprotectant solution (30% sucrose,
30% ethylene glycol in PBS). Frozen striatum were thawed,
homogenized in PBS (1:4 weight/volume) and kept at 220uC.
Immunostaining
Free-floating coronal sections were washed overnight in PBS to
remove cryoprotectant. Unless otherwise stated, all steps were
performed at room temperature with three 10 min washes in PBS-
TX (PBS with 0.3% triton X-100) between each step. For
diaminobenzidine (DAB) staining sections were treated with 10%
methanol and 3% H2O2 to inhibit endogenous peroxidases,
permeabilized in PBS-TX for 30 min and blocked in 5% NGS in
PBS-TX for 30 min. For non-fluorescence TH staining, sections
were incubated with primary antibody rabbit anti-TH (1:10,000,
Millipore) overnight at 4uC followed by secondary goat anti
rabbit-biotin (1:200 Jackson ImmunoResearch) for 1 hour at room
temperature. Sections were incubated with DAB (Vector labora-
tories) to visualize TH positive cells, rinsed in PBS, mounted on
superfrost slides (Fisher scientific) and coverslipped (Permount,
Sigma).
For immunofluorescence, sections were incubated with mouse
anti a-syn (4B12 1:1000, Signet) or mouse anti-NeuN (1:500,
Millipore) together with rabbit anti-TH (1:10,000, Millipore) or
mouse anti c-myc clone 9E10 (1:1000, Abcam) overnight at 4uC.
Sections immunostained with anti-TH and anti-NeuN were then
incubated with secondary goat anti rabbit-biotin (1:200, Jackson
ImmunoResearch) and goat anti mouse-cy3 (1:500, Jackson
ImmunoResearch) for 1 hour at room temperature followed by
streptavidin-alexa635 (1:200, Life Sciences) for 1 hour at room
temperature. Sections immunostained with either anti-c-myc or
anti-a-syn were incubated with goat anti rabbit-biotin or goat anti
mouse-biotin respectively (1:200, Jackson ImmunoResearch) for
1 hour at room temperature followed by streptavidin-alexa635 or
streptavidin-alexa555 respectively (1:200, Life Sciences) for 1 hour
at room temperature. Sections were mounted onto superfrost
slides, coverslipped with vectashield (Vector laboratories) and kept
at 4uC.
Western Blot
Protein concentration of striatal homogenates was determined
using BCA kit (Pierce) and 25 mg proteins were loaded onto
polyacrylamide gels (Nupage). For denatured Western blot,
protein samples were loaded onto Nupage 4–12% SDS-PAGE
gels and run according to the manufacturer instructions. Gels were
transferred onto 0.4 mm nitrocellulose membranes. For native gels,
non-denatured protein samples were loaded onto 4–16% Bis-Tris
native gels (Nupage) and run at 150V for 2 hours on ice. Native
gels were transferred onto PVDF membranes using 25V for
1 hour on ice. Following transfer, membranes were fixed in 8%
acetic acid for 15 minutes and rinsed with water. Both PVDF and
nitrocellulose membranes were incubated with mouse anti-a-syn
(4B12 1:1000, Signet) and rabbit anti-b-actin in blocking solution
(Li-Cor) overnight at 4uC. Membranes were then incubated with
goat anti mouse-IR800 and goat anti rabbit-IR680 for 1 hour in
blocking solution (Li-Cor) prior to imaging on an Odyssey imager.
CHIP-Mediated Degradation of Alpha-Synuclein
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Microscopy, stereology and image analysis
Fluorescence images were obtained on either a Zeiss LSM510
META confocal microscope with X20 magnification for fluores-
cence imaging or an Olympus BX51 microscope for DAB
imaging. At least 8 coronal sections per animal throughout the
SNpc were analyzed to determine tyrosine hydroxylase cell loss by
conducting unbiased stereology cell counting using the Olympus
CAST stereology software. An average of 300 cells in the SNpc
were analyzed for venusYFP fluorescence. For NeuN lesion
analysis, coronal sections were co-stained with anti TH and anti
NeuN antibodies. The SNpc was outlined using Fiji (NIH)
according to TH staining and was saved as a region of interest.
The amount of NeuN positive neurons only within that region was
calculated using Fiji’s particle analysis feature.
Statistics
Mann Whitney test was performed for all data sets. One-tail t-
test analysis was performed for neuronal lesion analysis presented
in Figures 3 and 4. Statistical analysis was performed using
GraphPad Prism software.
Supporting Information
Figure S1 Tissue staining and image analysis. To count
NeuN positive cells within the SNpc, coronal sections were co-
immmunostained with anti-TH antibody (purple) and anti-NeuN
(red). Merged image of TH and NeuN immunopoitive cells
(merge) illustrate the region in which NeuN counting was
conducted according to TH staining. The SNpc was delineated
ipsilateral and contralateral and defined as a region of interest
according to the TH immunostaining, which was then superim-
posed onto the NeuN image to allow particle analysis. NeuN
positive cells were counted within the defined region across the
SNpc of each animal. For the purpose of illustrating the image
analysis conducted in this assay a representative images of a CHIP
injected animal is presented.
(TIF)
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